Senate Follow-On Biologics Bill Still Stuck In Evergreen Forest
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite moving a bill out of committee last session, the Senate is still wrangling over the issue of whether modifications of existing products should get full exclusivity.
You may also be interested in...
Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says
Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.
Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says
Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.
Biosimilar Interchangeability Does Not Create Substitution Under House Bills
While biosimilars legislation is seen as a means of lowering health care costs, interchangeability provisions in House bills creating a biosimilars approval pathway would not be enough to allow automatic substitution at the pharmacy level - the route to the highest savings